Difference between revisions of "Mirvetuximab soravtansine (Elahere)"
m |
m |
||
| Line 17: | Line 17: | ||
[[Category:Protein expression-specific medications]] | [[Category:Protein expression-specific medications]] | ||
| − | [[Category: | + | [[Category:Anti-FOLR1 antibody-drug conjugates]] |
| − | |||
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] | ||
Revision as of 21:17, 30 June 2023
Mechanism of action
From the NCI Drug Dictionary: An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent’s efficacy in multidrug resistant tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 2022-11-14: Granted accelerated approval for adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. (Based on SORAYA)
Also known as
- Code name: IMGN853
- Generic name: mirvetuximab soravtansine-gynx
- Brand name: Elahere